Sheng Liu

Sheng Liu

Auto-generated profile, based on publicly available information

Sheng Liu

Department of Pharmacy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2024 in Clinical Therapeutics
Verified
Journal Article
Closed access
RWRui Wu
Rui Wu
GZGaochao Zhu
Gaochao Zhu
YJYinghui Ju
Yinghui Ju
YZYue Zhu
Yue Zhu
MWMenglin Wang
Menglin Wang
SLSheng Liu
Sheng Liu

22 March 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TTTong Tong
Tong Tong
PLPeifang Li
Peifang Li
HDHaiwen Ding
Haiwen Ding
YHYing Huang
Ying Huang
SLSheng Liu
Sheng Liu
Objective: Xuebijing injection (XBJ) is a commonly used herbal medicine injection in China. However, the physical compatibility of XBJ with other intravenous drugs remains unclear. The purpose of this research is to evaluate physical compatibility of Xuebijing injection (XBJ) with 53 intravenous drugs (including 31 Chinese medicine injections and 22 chemicals) during simulated Y-site administration.Methods: Y-site administration was simulated in vitro by admixing 0.33 ml/ml XBJ with an equal volume of other diluted 53 intravenous drugs, respectively. Physical compatibility including visual inspection, Tyndall beam, particle limits, turbidity, pH, chromacity value, spectroscopic absorption of 550 nm and 420 nm (A550 nmand A420 nm) were observed and assessed at 0, 1, 2, and 4 h. Physical compatibility was defined as all solutions with no color changes, no gas evolution, particulate formation and no Tyndall beam within 4 hours, turbidity changes <0.5 nephelometric turbidity unit (NTU) compared to 0 h, particle limits allowed by the Chinese Pharmacopoeia (Ch.P) 2020 edition, pH changes <10% compared to 0, chromacity value changes <200 compared to 0 h, or photometrical changes of A420 nm<0.0400 or A550 nm<0.0100 compared to 0 h.Results: XBJ was physically incompatible with 27 of the 53 intravenous drugs tested, 26 were compatible with XBJ for 4 h.Conclusions: XBJ should not be simultaneously co-administered with 27 of the 53 intravenous drugs during simulated Y-site. If coadministration was inevitable, flushing tube with NS or D5W before and after infusion of XBJ was needed. Assessment included visual inspection, Tyndall beam, turbidity measurement, particle counts, pH measurement, chromacity value measurement and absorption of A550 nmwere proved to be valid and robust for the quality control of infusion and compatibility of Chinese herbal injection.

1 February 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
HDHaiwen Ding
Haiwen Ding
TTTong Tong
Tong Tong
SLSheng Liu
Sheng Liu
LTLiqin Tang
Liqin Tang
ZCZhaolin Chen
Zhaolin Chen
Objective: Etoposide is an antineoplastic agent widely used to treat pediatric and adult cancers. Critically ill patients are expected to receive several intravenous pharmaceutical drugs while admitted to hospitals. When compatibility data are available, intravenous drugs may be administered simultaneously through the Y-site. This study aimed to determine the compatibility of etoposide during simulated Y-site administration with 45 continuous-infusion drugs that are commonly administered in tumor critical care units. Methods: Etoposide was diluted to a concentration of 0.25 mg/mL in 0.9% sodium chloride (NS) and other intravenously tested drugs were reconstituted according to the manufacturer’s recommendations to the final clinical desired concentrations. Y-site administration was simulated in vitro by mixing 5 mL etoposide with other diluted intravenous medications under aseptic conditions in a 1:1 ratio. Compatible solutions were withdrawn at certain time intervals (0, 1, 2, 4 hours) after mixing and tested visually, using a Tyndall beam, pH, turbidity, insoluble particles, and UV absorption as measures of compatibility. Results: Etoposide was compatible with 38 (84%) of the 45 drugs tested within four hours. Glutathione and human granulocyte colony-stimulating factor immediately showed incompatibility with etoposide. Within 1 h, four medications (cefuroxime sodium, ilaprazole sodium, mycophenolate, and xuebijing) were incompatible. Within 4 h, one medications (ceftazidime) were also found to be incompatible with etoposide under observation. Conclusion: Seven of the 45 common medications in tumor critical care tested with etoposide were incompatible within 4 h. If co administration is inevitable and the drug is infused through a port catheter, a larger volume of saline (NS) or dextrose 5% in water (D5W) should be used to flush the port catheter before and after the etoposide infusion to clean the lumen of the port catheter.

1 March 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
HDHaiwen Ding
Haiwen Ding
TTTong Tong
Tong Tong
SLSheng Liu
Sheng Liu
LTLiqin Tang
Liqin Tang
ZCZhaolin Chen
Zhaolin Chen
Corrigendum for the article Medication Safety in Intravenous Therapy: Compatibility of Etoposide with Frequently Drugs Used in Tumour Critical Care During Simulated Y-Site Administration